BR112017010599A2 - análogos de ureia ligada substituída como moduladores sirtuin - Google Patents

análogos de ureia ligada substituída como moduladores sirtuin

Info

Publication number
BR112017010599A2
BR112017010599A2 BR112017010599A BR112017010599A BR112017010599A2 BR 112017010599 A2 BR112017010599 A2 BR 112017010599A2 BR 112017010599 A BR112017010599 A BR 112017010599A BR 112017010599 A BR112017010599 A BR 112017010599A BR 112017010599 A2 BR112017010599 A2 BR 112017010599A2
Authority
BR
Brazil
Prior art keywords
diseases
disorders
substituted urea
sirtuin modulators
urea analogues
Prior art date
Application number
BR112017010599A
Other languages
English (en)
Inventor
Lamond Ellis James
Anderson Evans Karen
Andrew Seefeld Mark
Michael Fox Ryan
Henry Miller William
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112017010599A2 publication Critical patent/BR112017010599A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo "análogos de ureia ligada substituída como moduladores sirtuin" a presente invenção se refere a compostos análogos de ureia ligada substi-tuída, novos, da fórmula (i) ou seus sais farmaceuticamente aceitáveis, composi-ções farmacêuticas correspondentes, processos para fazer e usar tais compostos, individualmente ou em combinação com outros agentes terapêuticos, como modu-ladores sirtuin úteis para aumentar a vida útil de uma célula e no tratamento e/ou prevenção de uma ampla variedade de doenças e distúrbios, que incluem, porém não são limitados a, por exemplo, doenças ou distúrbios relacionados a envelheci-mento ou stress, obesidade, doenças neurodegenerativas, doença cardiovascular, distúrbios de coagulação de sangue, inflamação, câncer, e/ou rubor bem como do-enças ou distúrbios que se beneficiariam de atividade mitocondrial aumentada.
BR112017010599A 2014-11-19 2015-11-19 análogos de ureia ligada substituída como moduladores sirtuin BR112017010599A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
PCT/IB2015/058980 WO2016079711A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
BR112017010599A2 true BR112017010599A2 (pt) 2017-12-26

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
BR112017010595-0A BR112017010595A2 (pt) 2014-11-19 2015-11-19 análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína
BR112017010601A BR112017010601A2 (pt) 2014-11-19 2015-11-19 análogos de ureia substituídos em ponte como moduladores de sirtuínas
BR112017010599A BR112017010599A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligada substituída como moduladores sirtuin
BR112017010602A BR112017010602A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR112017010595-0A BR112017010595A2 (pt) 2014-11-19 2015-11-19 análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína
BR112017010601A BR112017010601A2 (pt) 2014-11-19 2015-11-19 análogos de ureia substituídos em ponte como moduladores de sirtuínas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017010602A BR112017010602A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Country Status (21)

Country Link
US (4) US10072011B2 (pt)
EP (4) EP3221317B1 (pt)
JP (4) JP6806679B2 (pt)
KR (4) KR20170083133A (pt)
CN (4) CN107207520A (pt)
AU (4) AU2015348942B2 (pt)
BR (4) BR112017010595A2 (pt)
CA (4) CA2968029A1 (pt)
CL (1) CL2017001275A1 (pt)
CO (1) CO2017004994A2 (pt)
CR (1) CR20170209A (pt)
DO (1) DOP2017000123A (pt)
EA (1) EA201791074A1 (pt)
ES (1) ES2823748T3 (pt)
IL (1) IL252252A0 (pt)
MX (1) MX2017006658A (pt)
PE (1) PE20171257A1 (pt)
PH (1) PH12017500913A1 (pt)
RU (3) RU2017120857A (pt)
SG (1) SG11201703824QA (pt)
WO (4) WO2016079710A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653782B2 (en) * 2014-11-25 2020-05-19 Nortwestern University Retroviral particles expressing Sirt1 embedded within PPCN
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
WO2021043703A1 (de) * 2019-09-02 2021-03-11 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
ES2574927T3 (es) * 2009-10-29 2016-06-23 Glaxosmithkline Llc Piridinas bicíclicas y análogos como moduladores de sirtuina
WO2013090369A1 (en) * 2011-12-12 2013-06-20 Smb Innovation Novel heterocyclic compounds useful in sirtuin binding and modulation
KR20160006215A (ko) * 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체

Also Published As

Publication number Publication date
CN107207520A (zh) 2017-09-26
WO2016079709A1 (en) 2016-05-26
JP2017534662A (ja) 2017-11-24
RU2017120858A (ru) 2018-12-19
AU2015348944A1 (en) 2017-06-01
CO2017004994A2 (es) 2017-09-20
EP3221316A1 (en) 2017-09-27
US20170355705A1 (en) 2017-12-14
RU2017120857A (ru) 2018-12-19
US20180319810A1 (en) 2018-11-08
EP3221317B1 (en) 2020-07-22
BR112017010595A2 (pt) 2018-01-02
AU2015348942A1 (en) 2017-06-01
CN107207509A (zh) 2017-09-26
WO2016079710A1 (en) 2016-05-26
CA2968032A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
BR112017010602A2 (pt) 2017-12-26
KR20170083133A (ko) 2017-07-17
US20170362234A1 (en) 2017-12-21
JP2017534664A (ja) 2017-11-24
JP2017534665A (ja) 2017-11-24
JP2017534663A (ja) 2017-11-24
EP3220918A1 (en) 2017-09-27
ES2823748T3 (es) 2021-05-10
WO2016079712A1 (en) 2016-05-26
CR20170209A (es) 2017-07-17
IL252252A0 (en) 2017-07-31
AU2015348942B2 (en) 2018-07-05
EP3221322A1 (en) 2017-09-27
KR20170083135A (ko) 2017-07-17
MX2017006658A (es) 2018-01-15
CA2968030A1 (en) 2016-05-26
EA201791074A1 (ru) 2017-10-31
JP6806679B2 (ja) 2021-01-06
PH12017500913A1 (en) 2017-12-04
DOP2017000123A (es) 2017-08-15
CN107108627A (zh) 2017-08-29
CA2968029A1 (en) 2016-05-26
EP3221317A1 (en) 2017-09-27
PE20171257A1 (es) 2017-08-28
CA2968027A1 (en) 2016-05-26
CN107207521A (zh) 2017-09-26
US10072011B2 (en) 2018-09-11
BR112017010601A2 (pt) 2017-12-26
RU2017120855A (ru) 2018-12-19
CN107207509B (zh) 2020-04-21
WO2016079711A1 (en) 2016-05-26
SG11201703824QA (en) 2017-06-29
KR20170083134A (ko) 2017-07-17
CL2017001275A1 (es) 2017-12-15
US20190048016A1 (en) 2019-02-14
AU2015348941A1 (en) 2017-06-01
KR20170087907A (ko) 2017-07-31

Similar Documents

Publication Publication Date Title
BR112017010599A2 (pt) análogos de ureia ligada substituída como moduladores sirtuin
BR112015028613A2 (pt) análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112015028879A2 (pt) derivados heterocíclicos
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
DOP2012000067A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de enzima de disociacion de app de sitio beta ( bace), composiciones, y su uso
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
DOP2012000051A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112014003704A2 (pt) moduladores ror gama
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112015019919A2 (pt) compostos bicíclicos
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]